Re: Deal of the year in biotech
It look like there's a plan to let Roche take on the RNA side of things if all goes well with GT, I suppose. Starting with DMD - the PMOs and the PPMOs.
But the PPMO can take us out of rare and into common diseases. Big populations here and abroad. Naturally that's where a Roche would fit in (both abroad and US). And other big players as well if that's how it plays out.
What ARE we doing in our PPMO RNA researches? What IS Gilmore up to? That's going to be interesting.The DMD PPMOs will get that ball rolling, but once they are out of hiding and working in the DMD kids then attention will turn to what THEY can do. Which I think is a lot, of course!